

TABLE OF CONTENTS

RATIFICATION PAGE	ii
STATEMENT PAGE	iii
FOREWORD	iv
ACKNOWLEDGEMENTS	v
ABSTRACT (ENGLISH)	vii
ABSTRACT (INDONESIAN)	viii
TABLE OF CONTENTS	ix
LIST OF TABLES	xiii
LIST OF FIGURES	xv
LIST OF ATTACHMENTS	xvi
LIST OF APPENDIXES	xvii
ABBREVIATIONS	1
CHAPTER I	2
A. Background	2
B. Problem Formulation	5
C. Study Objectives	5
1. General objective:.....	5
2. Specific objective:	5
D. Study Originality	6
E. Research Benefits	9
1. Academic	9
2. Community.....	9
3. Medical Professionals	9
4. Institution	9
CHAPTER II	10
A. Literature Review	10
1. Doping.....	10
1.1. Definition	10
1.2. Unintentional Doping.....	11
1.3. Reasoning behind Doping	12

1.4. Penalty of Doping	13
1.5. World Anti-Doping Agency (WADA)	14
1.6. Classification of Doping Substances.....	15
1.7. Cardiological Drug Classes Banned by WADA	16
1.7.1. <i>P1: Beta-blockers</i>	17
1.7.2. <i>S5: Diuretics</i>	18
1.7.3. <i>S5: Masking Agents</i>	20
2. Indonesian Anti-Doping Efforts	21
2.1. Prevalence of Doping	21
2.2. Prevalence of CVD in Indonesian Athletes	23
2.3. Anti-doping Efforts by IADO	23
3.7. Therapeutic Use Exemption on Cardiovascular Conditions	27
3. Pharmacological Properties	30
3.1. Composition	30
3.2. Administration route	31
3.3. Pharmacokinetics	37
4. Distribution of Drugs in Indonesia	41
4.1. Badan Pengawas Obat dan Makanan (BPOM)	41
4.2. PIONAS prescription type	42
5. Ranking Systems	44
5.1. The Jackson 5 System	44
5.2. Naranjo Adverse Drug Reaction Probability Scale.....	45
B. Theoretical Framework	47
C. Conceptual Framework	48
CHAPTER III	49
A. Study Design	49
1. Data Collection and Development of Ranking Tools	49
1.1. Prohibited Substances Master List	49
1.1.1. <i>Framework</i>	50
1.1.2. <i>Data Collection</i>	51
1.2. BPOM Doping Products Master List	56
1.2.1. <i>Framework</i>	57

1.2.2. <i>Data Collection</i>	58
1.3. Development of Ranking Tools	59
1.3.1. <i>Prescription Type Risk Scoring Tool</i>	59
1.3.2. <i>WADA Permission Risk Scoring Tool</i>	60
1.3.3. <i>Administration Route Risk Scoring Tool</i>	61
1.3.4. <i>Pharmacokinetic Uncertainty Risk Scoring Tool</i>	63
2. Creation of the Doping Risk Ranking System	64
3. Ranking of Risk	66
4. Reporting of Processed Data	67
B. Study Time and Setting	67
C. Study Population	67
D. Data Collection Tools	68
E. Study Variable	68
F. Operational Definition	68
G. Study Plan	69
H. Statistical Analysis	70
I. Ethical Consideration	70
CHAPTER IV	71
A. Research Results	71
1. Registered BPOM Products	71
1.1. Exclusion of Non-targeted Products	71
1.2. Products not circulating in Indonesia	74
1.2. Products circulating in Indonesia	74
2. Registered Products' WADA Permission	75
2.1. Beta-blockers' WADA Permission	75
2.2. Diuretics' WADA Permission	75
2.3. Masking Agents' WADA Permission.....	75
3. Registered Products' Prescription Type	76
3.1. Beta-blockers' Prescription Type.....	76
3.2. Diuretics' Prescription Type	76
3.3. Masking agents' Prescription Type.....	77
3.3.1. <i>Obat Bebas</i>	79

3.3.2. Obat Bebas Terbatas	79
3.3.3. Obat Keras	80
4. Registered Products' Routes of administration	80
4.1. Beta-blockers' Administration Route	80
4.2. Diuretics' Administration Route	81
4.3. Masking Agents' Administration Route	81
5. Registered Products' Pharmacokinetic Uncertainty Factors	83
5.1. Beta-blockers' Pharmacokinetic Uncertainty	83
5.2. Diuretics' Pharmacokinetic Uncertainty	83
5.3. Masking Agents' Pharmacokinetic Uncertainty	84
6. Doping Risk Ranking System	88
6.1. Beta-blocker Doping Risk Ranking System	88
6.2. Diuretic Doping Risk Ranking System	92
6.3. Masking Agent Doping Risk Ranking System	96
6.4. Registration Number and Brand Ranking	102
B. Discussion	103
1. International Cases and Significance of Study	103
2. National Cases and Significance of Study	103
3. Risk of Beta-blocker Products	104
4. Risk of Diuretic Products	105
5. Risk of Masking Agent Products	106
C. Research Limitations	107
CHAPTER V	109
A. Conclusions	109
B. Recommendations	109
REFERENCES	112
APPENDIX	121

LIST OF TABLES

Table 1. Study Originality	7
Table 2. WADA Classification of Prohibited Substances and Methods	16
Table 3. IADO Anti-Doping Case Disclosure (November 2023)	21
Table 4. WADA Complete List of Therapeutic Use Exemption.....	24
Table 5. Compositions of Beta-blockers, Diuretics, and Masking Agents	30
Table 6. Administration Route Characteristics	32
Table 7. Beta-blockers Pharmacological Data	38
Table 8. Diuretics Pharmacological Data	39
Table 9. Masking Agents Pharmacological Data	41
Table 10. Example of J5 System Ranking.....	45
Table 11. Example of Naranjo ADR Probability Scale.....	45
Table 12. Development of Prescription Type Scoring	60
Table 13. Development of WADA Permission Scoring	61
Table 14. Development of Administration Route Scoring.....	61
Table 15. Development of Pharmacokinetic Uncertainty Factor Scoring.....	63
Table 16. Doping Risk Ranking System	64
Table 17. Pharmacological Risks Scoring System.....	65
Table 18. Availability Risks Scoring System.....	65
Table 19. Operational Definition.....	68
Table 20. List of Unavailable Beta-blocker Substances.....	73
Table 21. List of Unavailable Diuretic Substances	73
Table 22. List of Unavailable Masking Agent Substances.....	73
Table 23. Distribution of available prohibited substance	74
Table 24. WADA Permission of Available Prohibited Substances	75
Table 25. Beta-blockers' Prescription Type.....	76
Table 26. Diuretics' Prescription Type	76
Table 27. Masking agents' Prescription Type.....	77
Table 28. Quantity of Beta-blockers with selected Administration Route.....	80
Table 29. Quantity of Diuretics with selected Route of Administration.....	81
Table 30. Quantity of Masking agents with selected Route of Administration ...	81

Table 31. Beta-blockers' Pharmacokinetic Uncertainty.....	83
Table 32. Diuretics' Pharmacokinetic Uncertainty	83
Table 33. Masking Agents' Pharmacokinetic Uncertainty.....	84
Table 34. Doping Risk Ranking System for Beta-blockers	85
Table 35. Doping Risk Ranking System for Diuretics	86
Table 36. Doping Risk Ranking System for Masking Agents	87
Table 37. Beta-blockers Ranking Score	88
Table 38. Beta-blockers Risk Ranking List.....	91
Table 39. Diuretics Ranking Score.....	92
Table 40. Diuretics Risk Ranking List	95
Table 41. Masking Agent Ranking Score.....	96
Table 42. Masking Agents Risk Ranking List	101

LIST OF FIGURES

Figure 1. Algorithm for assessing a TUE application for Beta-blockers	29
Figure 2. Theoretical Framework of Study	47
Figure 3. Conceptual Framework of Study	48
Figure 4. Flowchart for tools used in certain demographics	66
Figure 5. Research sampling flow	71
Figure 6. Distribution of Masking Agents Substances in Prescription Types	78

LIST OF ATTACHMENTS

Attachment 1. <i>Obat Bebas</i> Mark	42
Attachment 2. <i>Obat Bebas Terbatas</i> Mark & Warning Labels	43
Attachment 3. <i>Obat Keras & Psikotropika</i> Mark.....	43
Attachment 4. <i>Narkotika</i> Mark.....	43
Attachment 5. WADA Prohibited List 2024	49
Attachment 6. Example of the Prohibited Substances Master List	50
Attachment 7. Example of BPOM Doping Products Master List	56

LIST OF APPENDIXES

Appendix 1. Ethical Clearance	123
Appendix 2. Prohibited Substances Master List	124
Appendix 3. Flow of PSML Framework Development	125
Appendix 4. Flow of PSML Data Collection	129
Appendix 5. BPOM Doping Products Master List	146
Appendix 6. Flow of BPOM DPML Framework Development	147
Appendix 7. Flow of BPOM DPML Data Collection	152
Appendix 8. Table for Doping Risk of Official Medicines in BPOM	160

ABBREVIATIONS

β-AR	β-Adrenergic receptor
AAS	Anabolic-Androgenic Steroids
ADR	Adverse Drug Reaction
AR	Availability Risks
BPOM	Badan Pengawas Obat dan Makanan
CVD	Cardiovascular Disease
DPML	Doping Products Master List
EPO	Erythropoietin
GDP	Gross domestic product
Hb	Hemoglobin
IADO	Indonesia Anti-Doping Organization
IOC	International Olympic Committee
J5	Jackson 5
KONI	Komite Olahraga Nasional Indonesia
OTC	Over-the-Counter
PIONAS	Pusat Informasi Obat Nasional
PR	Pharmacological Risks
PSML	Prohibited Substances Master List
TUE	Therapeutic Use Exemption
TUEC	Therapeutic Use Exemption Committee
WADA	World Anti-Doping Agency